Non-Fermentative Gram-Negative Bacilli Flashcards

Classification and Distribution of Gram-Negative Bacilli

  • Categorization of Gram-Negative Bacilli based on metabolic fastidiousness and biochemical capabilities:
    • Nonfastidious Gram-Negative Bacilli:
    • Fermenters (63%63\% of isolates): Enterobacteriaceae spp.
    • Nonfermenters (20.3%20.3\% of isolates): Pseudomonas spp., Acinetobacter spp.
    • Fastidious Gram-Negative Bacilli:
    • Hemophilic (13%13\% of isolates): Haemophilus spp.
    • Fermenters and Nonfermenters (1%1\% of isolates): Haemophilus aphrophilus, Eikenella spp., Capnocytophaga spp.
    • Anaerobes (3%3\% of isolates): Bacteroides spp., Fusobacterium spp., Prevotella spp.

Taxonomic classification flowchart of Gram-negative bacilli

Characteristics of Non-Fermentative Gram-Negative Bacilli

  • Metabolic Profile:
    • Non-fermenters are incapable of catabolizing glucose via anaerobic fermentative pathways (they do not ferment glucose).
    • Inability to ferment glucose does not exclude other specific carbohydrates from being catabolized aerobically.
  • Environmental Distribution and Habitats:
    • Naturally occurring organisms widely distributed in environmental reservoirs such as soil and natural water sources.
    • Frequently colonize hospital equipment, humidifiers, contact lens cleaning solutions, and standing disinfectants.
  • Pathogenic Importance:
    • Function primarily as opportunistic pathogens.
    • Act as major causes of nosocomial (hospital-acquired) infections in susceptible populations.
  • Common Clinically Identified Species:
    • Pseudomonas species: Pseudomonas aeruginosa, Pseudomonas putida, Pseudomonas fluorescens.
    • Stenotrophomonas maltophilia.
    • Acinetobacter species.
    • Burkholderia species: Burkholderia cepacia, Burkholderia pseudomallei.

Pseudomonas aeruginosa: Key Morphology, Growth, and Laboratory Identification

  • Microscopic and Morphological Features:
    • Gram-negative rod (bacillus).
    • Motile by means of flagella.

3D rendering of motile rod-shaped Pseudomonas bacterium

  • Growth Conditions and Cultural Characteristics:

    • Strict Aerobe: Requires oxygen as terminal electron acceptor, but can grow under anaerobic conditions if nitrates (NO3−\text{NO}_3^-) are present.
    • Thermal Tolerance: Grows at 42 ∘C42\,^\circ\text{C}, a physiological parameter used to differentiate P. aeruginosa from other Pseudomonas species.
    • Isolation Media: Cultivatable on standard Blood Agar and selective MacConkey Agar (appears as a non-lactose fermenter).
    • Colony Appearance:
    • Flat, smooth colonies with regular or fuzzy margins.
    • Exhibits a characteristic metallic sheen or "crocodile skin-like" appearance.
    • Mixed colony morphologies may be observed within a single pure culture.
    • Hemolysis: Causes diffuse hemolysis on Blood Agar.
    • Odor: Produces a distinct sweet, fruity, or grape-like aroma.

  • Biochemical Reactions:

    • Oxidase Test: Positive.
    • Catalase Test: Positive.
    • Citrate Utilization: Positive.
    • Sugar Fermentation: Negative.
    • Nitrate Reduction: Positive (reduces nitrates to nitrites).
    • Aesculin Hydrolysis: Positive.

  • Pigment Production:

    • Pyocyanin: Blue-green pigment (specific to P. aeruginosa).
    • Pyoverdine: Yellow-green fluorescent pigment functioning as a siderophore.
    • Pyorubin: Red-brown pigment.
    • Pyomelanin: Black pigment.

Agar culture plate showing pyocyanin and pyorubin pigments produced by Pseudomonas aeruginosa

Virulence Factors and Pathogenesis of Pseudomonas aeruginosa

  • Structural and Surface-Bound Virulence Factors:
    • Flagellum: Enables motility and facilitates directional chemotaxis towards host surfaces.
    • Type IV Pili (Pilus): Mediates twitching motility and adherence to host epithelial cellular receptors.
    • Non-pilus Adhesins: Promote cellular attachment to tissue matrices.
    • Lipopolysaccharide (LPS): Endotoxic outer membrane component triggering host inflammatory signaling cascades.
    • Outer Membrane Proteins (OMPs): Maintain membrane structural integrity and mediate nutrient transport.
    • Alginate / Mucoid Exopolysaccharide (MEP) / Biofilm Matrix: Protects bacteria against host immune clearance (phagocytosis) and decreases antibiotic penetration; prominent in chronic pulmonary infections.
    • Type 3 Secretion System (T3SS): Syringe-like apparatus injecting effector toxins directly into host cytoplasm.

Cellular structures and secreted virulence factors of Pseudomonas aeruginosa including T3SS and biofilms

  • Extracellular Secreted Enzymes and Toxins:
    • Proteases:
    • LasB Elastase: Degrades structural elastin, collagen, and host immunoglobulins.
    • LasA Elastase: Acts synergistically to enhance LasB elastolytic activity.
    • Alkaline Protease: Cleaves host structural proteins and impairs host immune responses.
    • Hemolysins:
    • Phospholipase C: Cleaves membrane phospholipids, causing host cell membrane disruption and lysis.
    • Rhamnolipid: Solubilizes host lipids, inhibits mucociliary clearance in respiratory epithelium.
    • Exotoxin A: Inhibits eukaryotic protein synthesis by catalyzing ADP-ribosylation of elongation factor 2 (EF-2\text{EF-2}), leading to extensive host tissue necrosis.
    • Exoenzyme S: T3SS-secreted effector protein that disrupts host cell cytoskeleton and induces T-cell apoptosis.
    • Pyocyanin: Redox-active pigment that generates reactive oxygen species (ROS), causing oxidative stress, cytotoxicity in host tissue, and suppression of competing microflora.
    • Quorum Sensing Molecules: Cell-density dependent signaling molecules coordinating virulence factor production and biofilm maturation.
    • Siderophores: Scavenge host extracellular iron (e.g., pyoverdine).

Structural diagram of Pseudomonas cell showing virulence factors and extracellular products

Clinical Spectrum of Pseudomonas aeruginosa Infections

  • Commensal Status:
    • Transient commensal of the human upper respiratory tract and skin surface.
  • Opportunistic Pathogen in Vulnerable Populations:
    • Immunocompromised individuals, particularly burn injury patients.
    • Cystic Fibrosis (CF) pediatric and adult patients, leading to chronic endobronchial colonization and pulmonary damage.
  • Nosocomial (Healthcare-Associated) Infections:
    • Ventilator-Associated Pneumonia (VAP) in Intensive Care Unit (ICU) patients.
    • Catheter-related Urinary Tract Infections (UTIs).
    • Bed sores, surgical site infections, and severe burn wound infections.
  • Ophthalmic Infections:
    • Rapidly progressive corneal ulcers and keratitis, often associated with contaminated contact lens solutions.
  • Otic Infections:
    • Otitis externa ("swimmer's ear").

Antimicrobial Resistance Mechanisms and Treatment Strategies

  • Global Priority and ESKAPE Classification:

    • Classified by the World Health Organization (WHO) as one of the top three Critical Priority Pathogens urgently requiring novel antibiotic development.
    • Designated as a member of the ESKAPE multidrug-resistant pathogen group:
    • Enterococcus faecium
    • Staphylococcus aureus
    • Klebsiella pneumoniae
    • Acinetobacter baumannii
    • Pseudomonas aeruginosa
    • Enterobacter spp.

  • Mechanisms of Resistance in P. aeruginosa:

    • Intrinsic Resistance:
    • Constitutive low outer membrane permeability restricting drug entrance.
    • Overexpression of multidrug active efflux pump systems.
    • Production of drug-inactivating enzymes (e.g., chromosomal β-lactamases\beta\text{-lactamases} like AmpC).
    • Inherent resistance to Tetracycline, Chloramphenicol, Ertapenem, and standard β-lactams\beta\text{-lactams}.
    • Acquired Resistance:
    • Acquisition of resistance genes via Horizontal Gene Transfer (HGT) through plasmids or transposons.
    • Chromosomal mutations modifying drug targets or derepressing resistance pathways.
    • Adaptive Resistance:
    • Transient induction driven by continuous exposure to sub-inhibitory antibiotic concentrations.
    • Adaptation induced by environmental stress signals and biofilm formation.

Mechanisms of intrinsic, adaptive, and acquired antibiotic resistance in Pseudomonas aeruginosa

  • Resistance Trends and Pharmacotherapy:
    • Increasing prevalence of Multidrug-Resistant (MDR) and Extensively Drug-Resistant (XDR) strains, as well as high-level resistance in Acinetobacter species.
    • Rising rates of resistance to carbapenems (e.g., imipenem, meropenem).
    • Therapeutic Options:
    • Colistin (Polymyxin E) and Polymyxin B.
    • Tigecycline.
    • Advanced combination therapy regimens (e.g., ceftolozane/tazobactam).

Antimicrobial disk diffusion susceptibility testing plates for Pseudomonas aeruginosa

Infection Control Measures

  • Hand Hygiene: Rigorous adherence to hand hygiene protocol by healthcare workers.
  • Disinfection: Comprehensive decontamination and disinfection of hospital equipment, humidifiers, and ventilation tubing.
  • Patient Isolation: Implementation of contact isolation precautions for individuals colonized or infected with MDR or XDR strains.
  • Antimicrobial Stewardship: Reduction of unneeded broad-spectrum antibiotic usage to reduce selective pressure.
  • Surveillance: Routine surveillance cultures and monitoring within high-risk units such as Intensive Care Units (ICUs).

Clinical Discussion and Case Analysis

  • Clinical Scenario presentation:

    • Patient setting: Intensive Care Unit (ICU) patient on mechanical ventilation.
    • Clinical development: Patient develops hospital-acquired pneumonia.
    • Laboratory isolate profile:
    • Non-fermentative Gram-negative bacillus.
    • Oxidase test result: Positive.
    • Pigment: Blue-green (pyocyanin positive).
    • Antimicrobial susceptibility profile: Resistant to ceftazidime (3rd generation cephalosporin) and imipenem (carbapenem).

  • Clinical Evaluation and Diagnostic Reasoning:

    • Etiologic Agent: Pseudomonas aeruginosa.
    • Infection Type: Hospital-acquired Ventilator-Associated Pneumonia (VAP).
    • Clinical Nuance: Referring clinicians frequently provide insufficient clinical background details on laboratory test request forms, necessitating thorough microbiological profiling.
    • Resistance Interpretation: Resistance to both 3rd generation cephalosporins (ceftazidime) and carbapenems (imipenem) indicates a Multidrug-Resistant (MDR) P. aeruginosa strain.
    • Therapeutic Action Plan:
    • Immediate adjustment of empirical antimicrobial therapy.
    • Treatment options include colistin or novel combination agents such as ceftolozane/tazobactam, guided by definitive antimicrobial susceptibility testing.
    • Strict adherence to ICU infection control protocols to prevent cross-transmission.